Adherex Technologies Inc.

Adherex Technologies Inc.

April 03, 2006 08:24 ET

Adherex Announces Presentations on ADH-1 and Eniluracil at 2006 American Association of Cancer Research Annual Meeting

RESEARCH TRIANGLE PARK, NORTH CAROLINA--(CCNMatthews - April 3, 2006) - Adherex Technologies Inc. (TSX:AHX)(AMEX:ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that the Company will be giving three poster presentations - two on its lead biotechnology compound, ADH-1, and one on its oral dihydropyrimidine dehydrogenase (DPD) inhibitor, eniluracil - at the 97th Annual Meeting of the American Association of Cancer Research in Washington, DC, April 1-5, 2006:

- "Identification of ADH-1 products formed by incubation in human
plasma" by Mark J. Bednarcik, Mukur R. Gupta, Brian E. Huber and Jan
K. Losos - Sunday, April 2, 2006 at 1 p.m.

-"Pretreatment with eniluracil enhances the anti-tumor efficacy of
5-fluorouracil and capecitabine in human colorectal carcinoma bearing
nude-mice" by Jan K. Losos, Mukur. R. Gupta, Mark J. Bednarcik and
Brian E. Huber - Monday, April 3, 2006 at 8 a.m.

-"Immunohistochemical analysis of N-cadherin expression in human
tumors" by Brian E. Huber, Jan K. Losos, Rajesh K. Malik, Robin J.
Norris and William P. Peters - Tuesday, April 4, 2006 at 1 p.m.

In addition, a second poster on eniluracil will be presented by Dr.
Robert B. Diasio, Chairman, Department of Pharmacology and Toxicology
at the University of Alabama School of Medicine in Birmingham,
Alabama and Associate Director for Basic Sciences, UAB Comprehensive
Cancer Center, and his colleagues:

-"Dose dependent inhibition of uridine phosphorylase (UP) by
eniluracil (EU); Was the clinical inferiority of the EU/5-
fluorouracil (5-FU) Phase III trials due to an unrecognized
inhibition of 5-FU anabolism" by J. Fourie, V. Guarcello and R.B.
Diasio, University of Alabama at Birmingham, Birmingham, AL - Monday,
April 3, 2006 at 8 a.m.

Following the meeting, Adherex will make the posters available on its website at

About Adherex Technologies

Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. We aim to be a leader in developing innovative treatments that address important unmet medical needs in cancer. We currently have multiple products in the clinical stage of development, including ADH-1 (Exherin™), eniluracil and sodium thiosulfate (STS). ADH-1, our lead biotechnology compound, selectively targets N-cadherin, a protein present on certain tumor cells and established blood vessels that feed solid tumors. Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, was previously under development by GlaxoSmithKline for oncology indications. STS, a drug from our specialty pharmaceuticals pipeline, protects against the disabling hearing loss that can often result from treatment with platinum-based chemotherapy drugs. With a diversified portfolio of unique preclinical and clinical-stage cancer compounds and a management team with expertise in identifying, developing and commercializing novel cancer therapeutics, Adherex is emerging as a pioneering oncology company. For more information, please visit our website at

This press release may contain forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the Company might differ materially from the results, performance or achievements of the Company expressed or implied by such forward-looking statements. We are subject to various risks inherent in the biopharmaceutical industry, including our reliance on collaborative partners, the uncertainties of clinical trials, drug development and regulatory review, the early stage of our product candidates, our need for additional capital to fund our operations, and our history of losses. For a more detailed discussion of related risk factors, please refer to our public filings available at and

Contact Information

  • Adherex Technologies Inc.
    Melissa Matson
    Director, Corporate Communications
    (919) 484-8484